Click here to see it on AdPharm

AdPharm is the largest online pharmaceutical advertising gallery. It is subscription-based with various subscriptions plans available here.

Click here to see it on AdPharm

AdPharm is the largest online pharmaceutical advertising gallery. It is subscription-based with various subscriptions plans available here.

Click here to see it on AdPharm

AdPharm is the largest online pharmaceutical advertising gallery. It is subscription-based with various subscriptions plans available here.

Her passion: Community service
Her power: Lantus 24-hour insulin

Ask your doctor about the easy-to-use Lantus SoloStar pen

Insulin glargine, marketed by Sanofi-Aventis under the name Lantus, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. Its advantage is that it has a duration of action of 24 hours, with a “less peaked” profile than NPH. Thus, it more closely resembles the basal insulin secretion of the normal pancreatic beta cells. In type 2 diabetes and in combination with a short acting sulfonylurea (drugs which stimulate the pancreas to make more insulin), it can offer moderate control of serum glucose levels. In the absence of endogenous insulin (Type 1 diabetes or depleted type 2), Lantus needs the support of a fast acting insulin taken with food to reduce the effect of prandially derived glucose. It is fasting glucose elevation which more significantly affects HbA1c and thus determines the progression of the long-term complications of diabetes mellitus.

More on Wikipedia

Brand name: Lantus
Generic name/category: Insulin glargine, Anti-diabetic drugs, Insulin therapies, Human proteins, Recombinant proteins, Peptide hormones
Company: Sanofi-Aventis
Country/Market: USA, North America
Indication(s)/use:
Target: Consumers (DTC)
Tagline: Tag
Medium: Print ad
Size/duration: One third of page plus one single-page
Publication/Aired: Diabetic Living – Fall 2009

To see all of this brand's ads on AdPharm, click here
1 views
Sep 07, 2009

Visit AdPharm.net for more pharmaceutical ads

Designed to last

Enduring efficacy in Psoriasis.

Raptiva has a proven favorable safety profile with more than 10 years clinical experience in psoriasis.

Efalizumab (trade name Raptiva, Genentech, Merck Serono) is a medication designed to treat psoriasis. As its name implies, it is a recombinant humanized monoclonal antibody that binds to CD11a and acts as an immunosuppressant. It is administered once weekly by subcutaneous injection. It acts to inhibit white blood cell migration out of blood vessels into tissues. Because it suppresses the immune system, it has been associated with fatal brain infections, and has been withdrawn from the market.

More on Wikipedia

Brand name: Raptiva
Generic name/category: Efalizumab, Monoclonal antibodies, Recombinant proteins, Immunosuppressants, Withdrawn drugs
Company: Merck Serono
Country/Market: UK, Europe
Indication(s)/use: Psoriasis
Target: Healthcare Professionals (HCP)
Tagline: Enduring disease reduction
Medium: Print ad
Size/duration: single-page
0 views
Aug 17, 2009

Visit AdPharm.net for more pharmaceutical ads